Part III [motor examination], S&E ADL scale, use of an assistive device) and caregiver burden, a significant association also exists between basic cognitive functioning, as measured by the MMSE and caregiver stress.
AZILECT([R]) 1 mg/day early-start met all endpoints of the primary analysis: less deterioration in UPDRS
score than placebo between weeks 12 and 36; less worsening than delayed-start in UPDRS
score in comparing change between baseline and week 72 despite being on the same medication for the last 9 months; and non-inferiority to delayed-start in rate of deterioration between weeks 48 and 72.
No differences were observed between groups on the Schwab and England Activities of Daily Living Scale part of the UPDRS
or the Clinical Global Impression Scale severity of illness subscale.
Significant improvements with low-dose safinamide were also noted on the UPDRS
Part II Activities of Daily Living Score, the Euro-QoL, and the Clinical Global Impression-C.
The key secondary endpoint was motoric tolerability as measured using Parts II and III of the UPDRS
In these patients, the adjusted mean change in the UPDRS
II+III score from baseline to week 18 was -5.
The early-start group, which began rasagiline at the start of TEMPO, maintained a 17% higher UPDRS
score (about 2.
The following table shows mean change from baseline in UPDRS
, Part III (Motor) Score:
Gracies noted in an interview that centers that routinely conduct bilateral surgery often see a 50%-80% improvement in UPDRS
The primary analyses of the trial were based on change in total UPDRS
(Unified Parkinson's Disease Rating Scale) and included slope superiority of rasagiline over placebo in the placebo-controlled phase, change from baseline to week 72, and non-inferiority of early-start vs.
motor scores were comparable for both genders at onset and the rate of degeneration did not differ between genders.
Substantial improvements from the baseline in UPDRS
motor sub-score off medication (44% at year four) and patient reported quality of life scores (23% at year four) have been reported during the last four years, and the presentations today provide details of patient follow-up through year five.